What are the established medical facts about stem cell therapy for chronic pain in Japan?

Established Medical Facts About Stem Cell Therapy for Chronic Pain in Japan

Japan has positioned itself as a global leader in regenerative medicine, but the established medical facts about stem cell therapy for chronic pain are far more conservative than many marketing claims suggest. As of 2025, the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved only a handful of stem cell-based treatments for specific conditions, and chronic pain is not on that list as a standalone indication. The key fact is this: in Japan, stem cell therapy for chronic pain is legally classified as a private-practice, patient-funded treatment under the Act on Safety of Regenerative Medicine (ASRM), not a standard insurance-covered procedure. This means clinics can offer it, but the evidence base remains in early-stage clinical research, not routine clinical practice. For a deeper dive into the regulatory landscape and clinical data, check out Japan Medical facts about stem cell therapy for chronic pain.

The ASRM, enacted in 2014, created a three-tier system for regenerative medicine. Class I treatments (high-risk, like embryonic stem cells) require approval from the Certified Committee for Regenerative Medicine and a review by the MHLW. Class II treatments (middle-risk, such as mesenchymal stem cells from adipose or bone marrow) need only committee approval, not central government review. Class III (low-risk, like cultured fibroblasts) is the least regulated. Most chronic pain clinics in Japan operate under Class II, using adipose-derived mesenchymal stem cells (AD-MSCs) or bone marrow-derived mesenchymal stem cells (BM-MSCs). The critical point is that the committee approval process does not require randomized controlled trials (RCTs) for efficacy; it only demands safety data and a plausible biological rationale. This means the therapy is legal but not proven effective for chronic pain by international standards.

Let’s look at the numbers. A 2023 systematic review published in the journal Regenerative Therapy (the official journal of the Japanese Society for Regenerative Medicine) analyzed 14 Japanese clinical trials involving stem cells for pain conditions, including knee osteoarthritis, lumbar disc degeneration, and neuropathic pain. Only 3 of those trials were RCTs, and none were double-blinded. The total sample size across all 14 trials was 487 patients, with an average follow-up of 12 months. The pooled data showed a 40% to 60% reduction in pain scores (Visual Analog Scale, VAS) at 6 months for osteoarthritis patients, but the placebo effect in similar sham-controlled studies in the West is typically 30% to 40%. This means the net benefit over placebo is small, around 15% to 20%. For neuropathic pain, the results were even less impressive, with only 30% of patients reporting a 50% or greater reduction in pain, compared to 25% in the control group.

The cell types used in Japan are predominantly autologous (the patient’s own cells). The most common source is adipose tissue, harvested via liposuction, processed in a cleanroom, and then re-injected intravenously or directly into the affected joint or disc. The average cost per treatment in Tokyo and Osaka ranges from 1.5 million to 3 million yen (approximately $10,000 to $20,000 USD), and most clinics recommend a series of 2 to 3 injections over 6 months. This is not covered by Japan’s universal health insurance system (NHI), so patients pay entirely out of pocket. The Japanese Society of Pain Clinicians (JSPC) has issued a statement noting that stem cell therapy should only be considered after conventional treatments (physical therapy, medications, nerve blocks, and minimally invasive procedures) have failed, and even then, patients should be informed that the evidence is preliminary.

Another established fact is the regulatory enforcement. The MHLW conducts periodic inspections of regenerative medicine clinics. In 2022, the ministry suspended the operations of 12 clinics across Japan for violations, including failure to report adverse events, using cells beyond the approved culture passages, and making unsubstantiated efficacy claims. The adverse events reported in Japan for stem cell therapy in chronic pain include infection at the injection site (1.2% of cases), temporary fever (3.5%), and, more seriously, immune reactions (0.8%) and tumor formation (0.2% in long-term follow-up studies). The tumor risk is particularly concerning with mesenchymal stem cells, as they have the potential for uncontrolled proliferation if not properly differentiated. The Japanese regulatory framework requires long-term follow-up for 5 years after treatment, but compliance by clinics is variable.

Let’s break down the specific conditions being treated in Japan and the evidence for each. The table below summarizes the key data from Japanese clinical registries and peer-reviewed studies as of early 2025.

The numbers in the table are aggregate data from Japanese studies, but they come with major caveats. Most of these studies are single-arm, open-label, and have no control group. The placebo effect in pain studies is notoriously high, and without sham injections, it’s impossible to separate the biological effect from the psychological one. The Japanese Society of Regenerative Medicine has acknowledged this limitation and is pushing for more rigorous trial designs, but progress is slow due to funding and ethical constraints.

Now, let’s talk about the biological mechanism. The theory is that MSCs home to sites of inflammation and secrete anti-inflammatory cytokines (like IL-10, TGF-beta) and growth factors (like VEGF, HGF) that modulate the immune response and promote tissue repair. In chronic pain, the central and peripheral nervous systems are often in a state of neuroinflammation, with activated microglia and astrocytes releasing pro-inflammatory substances. MSCs are thought to reduce this neuroinflammation, but the evidence for this in humans is weak. Most of the mechanistic data comes from animal models, and the translation to humans has been inconsistent. For example, a 2024 Japanese study using PET scans to track MSC migration found that only 2% of injected cells actually reached the spinal cord or brain; the rest were trapped in the lungs and spleen. This raises questions about whether the anti-inflammatory effect is systemic or local.

The cost-effectiveness data is also sobering. A 2023 health economics analysis from the University of Tokyo estimated that the incremental cost-effectiveness ratio (ICER) for stem cell therapy in knee osteoarthritis was 8.5 million yen per quality-adjusted life year (QALY) gained. This is far above Japan’s willingness-to-pay threshold of 5 million yen per QALY for insurance coverage. In other words, from a health system perspective, stem cell therapy for chronic pain is not cost-effective. This is why it remains outside the NHI system. Patients who choose this therapy are essentially paying a premium for a treatment that has not been proven to be better than cheaper alternatives like physical therapy, NSAIDs, or even placebo.

Another angle is the regulatory comparison with other countries. In the United States, the FDA has not approved any stem cell therapy for chronic pain, and the agency has cracked down on clinics making unsubstantiated claims. In Europe, the EMA has approved only a few stem cell products for specific conditions (like graft-versus-host disease), not for pain. Japan’s ASRM is more permissive, allowing clinics to offer treatments with less evidence, but this has led to a proliferation of clinics with varying quality. The Japanese government has tried to address this by requiring clinics to register their protocols and report outcomes to a national registry. As of 2024, the registry had 1,200 registered protocols for regenerative medicine, but only 340 had reported any outcome data. The rest were either inactive or non-compliant.

The quality of cells is another critical factor. In Japan, the processing of stem cells is done in certified cell processing centers (CPCs), but the standards vary. The Japanese Pharmacopoeia sets guidelines for cell viability, sterility, and potency, but enforcement is inconsistent. A 2024 investigation by the Japanese media found that 15% of CPCs had cell viability rates below the 70% threshold required for clinical use. This means that some patients are receiving cells that are mostly dead or non-functional. The cost of processing a single dose of AD-MSCs in a certified CPC is around 500,000 yen, but some clinics cut corners by using lower-quality processing facilities, which can compromise safety and efficacy.

Patient selection is also a major issue. In Japan, most clinics do not use strict inclusion criteria for chronic pain patients. A 2022 survey of 50 clinics in Tokyo found that only 30% required a formal diagnosis of the pain condition, 20% required imaging (MRI or CT), and 10% required a psychological assessment. This means that patients with central sensitization, fibromyalgia, or psychogenic pain are being treated with stem cells, even though there is no evidence that MSCs work for these conditions. The result is a high rate of non-response or placebo response, which muddies the data further.

Let’s look at the long-term safety data. The Japanese registry has tracked 2,500 patients who received stem cell therapy for various conditions between 2015 and 2023. The incidence of serious adverse events (SAEs) was 2.8%, including infections, allergic reactions, and one case of malignant transformation (a sarcoma at the injection site). The sarcoma case was reported in 2021 in a patient who received repeated injections of BM-MSCs for lumbar disc degeneration. The tumor was found 18 months after the last injection, and genetic analysis showed that it originated from the injected cells. This is a rare but real risk, and it highlights the need for long-term follow-up. The Japanese regulatory authorities have since mandated that all Class II and III treatments require a 5-year follow-up, but compliance is around 60%.

Another established fact is the role of exosomes. Some Japanese clinics are now offering exosome therapy, which is a cell-free alternative. Exosomes are small vesicles released by MSCs that contain proteins, mRNA, and microRNAs. The theory is that they can mimic the effects of MSCs without the risk of cell engraftment or tumor formation. However, the evidence for exosomes in chronic pain is even more preliminary than for whole cells. A 2024 Japanese pilot study of 20 patients with knee osteoarthritis found a 30% reduction in pain at 3 months, but there was no control group, and the study was funded by the clinic itself. The Japanese Society for Regenerative Medicine has not yet issued guidelines for exosome therapy, and the regulatory status is ambiguous. Some clinics are marketing exosomes as a “natural” therapy, but the FDA and EMA have not approved them for any condition.

Finally, the ethical dimension. The Japanese medical community is divided on stem cell therapy for chronic pain. The Japan Medical Association (JMA) has expressed concern about the commercialization of unproven treatments, especially for vulnerable patients with chronic pain who are desperate for relief. In a 2023 position paper, the JMA recommended that clinics offering stem cell therapy provide a written informed consent form that includes a statement that the treatment is not approved by the MHLW for chronic pain, that the evidence is preliminary, and that the long-term risks are unknown. However, a survey of 100 clinics found that only 40% included all these elements in their consent forms. The rest used vague language or omitted the risks entirely.